“So we're, therefore, not anticipating a significant impact to our GARDASIL performance in China as a result of what we're seeing in Shanghai at this moment in time.”

In context

“anufacturing? And in that context, should we think about cadence -- or should we think about cadence over the year being notably different than in the years past? There's just a lot of different crosses play. So any color there would be helpful. Caroline Litchfield: Carter, this is Caroline. Thank you very much for the question. GARDASIL continues to be a great growth driver for our company globally, including China. Specific to China, we saw strong performance in the quarter, and we expect continued strong performance as we go through this year. We have significant demand in China. And as they're off flares, as a result of COVID and potentially lockdown in one part of the country, we have the ability to ensure that we're supplying more of the GARDASIL doses to other parts of the country. So we're, therefore, not anticipating a significant impact to our GARDASIL performance in China as a result of what we're seeing in Shanghai at this moment in time. As it pertains to our supply chain, our company has a very robust supply chain. And we have Plan A and Plan B, if there are any interruptions in the supply chain. So we, again, have no concern for the reliability of our supply chain, but we remain vigilant and focused on the situation at hand. Operator: Thank you. Next up, we have Mohit Bansal from Wells Fargo. Your line is open. Mohit Bansal: Congrats on the quarter. So one question we're getting a lot is, how do you feel about potential challenge from a competitor or for PDL1 and TIGIT combo, potentially looking better than KEYTRUDA first-line PD-L1-high lung cancer? Do you see this as a major threat, especially looking at the Phase II data from that competitor TIGIT? Dr. Dean Li: Thank you for that question. So I just wanted to emphasi”